E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Stroke and high blood pressure |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal research objective is to demonstrate that recruitment into the trial is possible (we would like to demonstrate enrolment of at least four patients per month). |
|
E.2.2 | Secondary objectives of the trial |
To report the proportion of suspected acute stroke patients admitted to research sites during the trial duration who fulfilled the study eligibility criteria.
To report the proportion of study eligible patients attended by a research-trained paramedic.
To report the proportion of study eligible patients enrolled into the study by a research-trained paramedic.
To report the proportion of study eligible patients approached about the research study but not enrolled, and to report reasons for non-enrolment where possible.
To report the proportion of study eligible patients not approached about the research study, and to report reasons for non-approach where possible.
To determine the additional time spent on scene by research-trained paramedics to enrol a participant into the study.
To report paramedic compliance with study data collection.
To report hospital staff compliance with study medication administration and data collection.
To report the proportion of study |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Adults ≥ 40 years old • New unilateral arm weakness thought to be due to acute stroke within 3 hours of symptom onset • Hypertension as defined by systolic BP >160mm Hg on two consecutive seated or lying readings taken 5 – 10 minutes apart • Conscious (eyes open spontaneously ie “A” on Alert, Voice, Pain, Unresponsive (AVPU) scale) • Patient being transported to a PIL-FAST trial site (i.e. Royal Victoria Infirmary, North Tyneside General Hospital and Wansbeck General Hospital) • Verbal consent obtained from participant or next of kin |
|
E.4 | Principal exclusion criteria |
• Age < 40 years • Females who are pregnant, lactating or at risk of pregnancy (i.e. who are not surgically sterile or at least 1 year post last menstrual period). Females < 56 years of age consented by a relative will be excluded as menstrual history may be unknown • Any presentation of suspected stroke without unilateral arm weakness • Cannot establish that stroke onset time (ie when patient was last seen well without symptoms) was within the last 3 hours • Systolic BP < 160mm Hg • Reduced level of consciousness (below “A” on AVPU scale) • Patient not being transported to PIL-FAST trial site • Absence of participant or next of kin consent • Known to be taking ACE-inhibitor or Angiotensin II Receptor Blocker medication already • Known sensitivity to lisinopril or other ACE-inhibitor medication • Pulse > 120 beats per minute • Seizure activity in this illness episode (witnessed or history) • Hypoglycaemia (blood glucose < 3.5 mmols/l) • Cannot walk independently prior to stroke (walking stick / frame is allowed) • Obvious understanding or memory problems when next of kin is absent • Significant head trauma or brain surgery in the last 3 months • Known renal failure • Known liver failure (or currently jaundiced) • Uncontrolled heart failure (breathlessness at rest) • Receiving palliative care for known malignancy • Currently enrolled in a clinical trial assessing a study drug |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is the number of participants enrolled in the study per month. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |